Annual Report 2021

Share this page

Creating tomorrow’s solutions

WACKER BIOSOLUTIONS

In 2021, WACKER BIOSOLUTIONS grew its sales 20.4 percent to €296.4 million (2020: €246.1 million), chiefly due to volume growth in biologics and cyclodextrins, and to improved prices. Exchange-rate effects dampened sales growth slightly. Sales increased across all regions.

At €38.6 million, EBITDA was at the prior-year level (2020: €38.1 million). Integration costs for the new site in San Diego, California (USA) reduced EBITDA. The EBITDA margin was 13.0 percent (2020: 15.5 percent).

Capital expenditures rose 68.3 percent year over year to €33.5 million (2020: €19.9 million), with one point of focus being expansion of the production plant in Amsterdam. The takeover of Genopis Inc. in the USA broadened WACKER BIOSOLUTIONS’ product portfolio to include pDNA technology and strengthened its presence in the key US biopharmaceutical market.

As of December 31, 2021, the number of employees at the division had decreased to 751 (Dec. 31, 2020: 764 ).

Key Data: WACKER BIOSOLUTIONS

 

 

 

 

 

€ million

 

2021

 

2020

 

2019

 

2018

 

2017

 

 

 

 

 

 

 

 

 

 

 

Total sales

 

296.4

 

246.1

 

243.0

 

227.0

 

205.9

EBITDA

 

38.6

 

38.1

 

31.1

 

23.5

 

37.5

EBITDA margin (%)

 

13.0

 

15.5

 

12.8

 

10.4

 

18.2

EBIT

 

20.7

 

21.6

 

14.0

 

9.8

 

26.1

Capital expenditures

 

33.5

 

19.9

 

13.2

 

17.9

 

15.7

R&D expenses

 

5.6

 

5.7

 

6.4

 

6.3

 

6.0

Employees (December 31, number)

 

751

 

764

 

754

 

709

 

533

Cyclodextrins
Cyclodextrins belong to the family of cyclic oligosaccharides (i.e. ring-shaped sugar molecules). They are able to encapsulate foreign substances such as fragrances and to release active ingredients at a controlled rate. WACKER BIOSOLUTIONS produces and markets cyclodextrins.
EBITDA
Earnings before interest, taxes, depreciation and amortization.